United States — Food and Drug Administration & Nathan Miller

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a Complete Response Letter to Aldeyra Therapeutics, citing a lack of substantial evidence for the efficacy of reproxalap, which triggered the stock price drop and subsequent lawsuits.

Nathan Miller: Nathan Miller is a Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, assisting with investor inquiries regarding the Aldeyra Therapeutics class action.

United States — Food and Drug Administration: The United States — Food and Drug Administration issued safety warnings concerning serious neurological complications in dogs related to Zoetis' Bedinvetmab, contributing to its weakening adoption.

Nathan Miller: Nathan Miller is the Client Relations Manager for Bronstein, Gewirtz & Grossman, LLC, assisting investors in joining the class action lawsuit against Zoetis.

United States — Food and Drug Administration: The FDA rejected Replimune's BLA and published briefing documents raising concerns about the data package, triggering the stock drop and subsequent lawsuits. The FDA's actions are central to the event.

Nathan Miller: Nathan Miller is the Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, serving as a contact for investors. His involvement is administrative and does not bear direct market impact.

United States — Food and Drug Administration: The FDA placed a full clinical hold on ARD-101's IND, halting all ongoing studies. This regulatory action is central to the lawsuit and has severely impacted Aardvark's operations and stock price.

Nathan Miller: Nathan Miller is the Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, providing contact for investors. His role is administrative in the class action.

United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.

Nathan Miller: Client relations manager at Bronstein, Gewirtz & Grossman.

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter to ImmunityBio regarding misleading efficacy claims made by Patrick Soon-Shiong about Anktiva, which triggered the stock price drop and subsequent lawsuits.

Nathan Miller: Nathan Miller is a Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, providing contact information for investors interested in the class action lawsuit.